Inactive Instrument

IceCure Medical Ltd Stock TEL AVIV STOCK EXCHANGE

Equities

ICCM

IL0011224156

Advanced Medical Equipment & Technology

Sales 2024 * 3.97M 1.43B Sales 2025 * 7.97M 2.88B Capitalization 35.94M 13B
Net income 2024 * -13M -4.7B Net income 2025 * -13M -4.7B EV / Sales 2024 * 9.06 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.51 x
P/E ratio 2024 *
-2.68 x
P/E ratio 2025 *
-2.85 x
Employees 74
Yield 2024 *
-
Yield 2025 *
-
Free-Float 43.44%
More Fundamentals * Assessed data
Dynamic Chart
IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense CI
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes CI
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025 CI
Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000 MT
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024 CI
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense CI
Transcript : IceCure Medical Ltd, 2023 Earnings Call, Apr 03, 2024
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IceCure Medical Seeks FDA Clearance for Cryoablation Technology MT
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes CI
Alliance Global Partners Adjusts IceCure Medical Price Target to $2.90 From $1.90, Maintains Buy Rating MT
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study CI
IceCure Medical Ltd. Announces Results from an Independent Study CI
More news
Managers TitleAgeSince
Chief Executive Officer 63 16-08-31
Director of Finance/CFO 54 17-04-30
Chief Tech/Sci/R&D Officer 48 18-03-24
Members of the board TitleAgeSince
Director/Board Member 73 12-08-14
Director/Board Member 68 13-07-31
Director/Board Member 61 22-12-03
More insiders
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
More about the company